Advertisement

Neurobiochemische Untersuchungen bei Akut- und Langzeitbehandlung mit Neuroleptika

  • E. Rüther
  • F. Müller-Spahn
Conference paper
Part of the Tropon-Symposium book series (BAYERZNS, volume 2)

Zusammenfassung

Neurobiochemische Untersuchungen bei der Akut- und Langzeitbehandlung mit Neuroleptika (NL) haben zwei Ziele:
  1. 1.

    Aufklärung des Wirkungsmechanismus der NL.

     
  2. 2.

    Optimierung der Therapie.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ackenheil M (1981) Biochemical effects of apomorphine: contribution to schizophrenia research. In: Corsini GU, Gessa GL (eds) Apomorphine and other dopaminomimetics, vol 2. Raven Press, New York, pp 215–224Google Scholar
  2. Andén NE (1970) Effects of amphetamine and some other drugs on central catecholamine mechanisms. In: Costa E, Garattini S (eds) Amphetamines and related compounds. Raven Press, New York, pp 447–462Google Scholar
  3. Andén NE, Rods BE, Werdenius B (1964) Effects of chlorpromazine, haloperidol and reserpine on the level of phenolic acids in rabbit corpus striatum. Life Sci 3: 149–158CrossRefGoogle Scholar
  4. Aratö M, Endrös A, Polgar M (1979) Endocrinological changes in patients with sexual dysfunction under long-term neuroleptic treatment. Pharmacopsychiat 12: 426CrossRefGoogle Scholar
  5. Bowers MB (1973) 5-hydroxyindolacetic acid (5-HIAA) and homovanillic acid (HVA) following probenecide in acute psychotic patients with phenothiazines. Psychopharmacologica 28:309–318CrossRefGoogle Scholar
  6. Bowers MB, Gold BJ, Roth RH (1980) CSF-Gaba in psychotic disorders. Psychopharmacologica 70: 279–282CrossRefGoogle Scholar
  7. Bowers MB, Henninger GR (1981) Cerobrospinal fluid homovanillic acid patterns during treatment. Psychiatr Res 4: 285–290CrossRefGoogle Scholar
  8. Bowers MB, Rozitis A (1974) Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs. J Pharm Pharmacol 26: 743–745PubMedCrossRefGoogle Scholar
  9. Bunney BS, Grace AA (1978) Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 23: 1715–1729PubMedCrossRefGoogle Scholar
  10. Chouinard G, Annable L, Jones BD, Collu R (1981) Lack of tolerance to long-term neuroleptic- treatment in dopamine tuberoinfundibular system. Acta Psychiatr Scand 64: 353–362PubMedCrossRefGoogle Scholar
  11. Costa E, Cheney DL, Mao CC, Moroni F (1978) Action of antischizophrenic drugs on the metabolism of y-aminobutyric acid and acetylcholine in globus pallidus, striatum and n. accumbens. Fed Proc 37: 2408–2414PubMedGoogle Scholar
  12. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical pharmacological potencies of antischizophrenic drugs. Science 192: 481–483PubMedCrossRefGoogle Scholar
  13. Davis JM, Vogel C, Gibbons R, Pavkovic J, Zhang M (1984) Pharmacoendocrinology of schizophrenia. In: Brown GM (ed) Neuroendocrinology and psychiatric disorders. Raven Press, New York, pp 29–54Google Scholar
  14. De Rivera JL, Lal S, Ettigi P, Hontela S, Muller HF, Friesen HG (1976) Effect of acute and chronic neuroleptica therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol 5: 273–282CrossRefGoogle Scholar
  15. Emrich H, Höllt V, Bergman M, Kissling M, Schmid W, Zerssen D, Herz A (1980) Plasma levels of beta-endorphine in schizophrenic patients. In: Costa E, Tabucchi M (eds) Neuropeptides and neuronal communications. Raven Press, New York, pp 489–502Google Scholar
  16. Freemann AS, Bunney BS (1987) Chronic neuroleptic effects on dopamine neuron activity: a model for predicting therapeutic efficacy and side effects? In: Dahl SG, Gram LF, Paul SM, Potter Z (eds) Clinical pharmacology in psychiatry (Psychopharmacology Serie 3 ). Springer, Berlin Heidelberg New York Tokyo, pp 223–235Google Scholar
  17. Langer DH, Brown GL, Docherty JP (1981) Dopamine receptors supersensitivity and schizophrenia: a review. Schizophr Bull 7 (2): 208–224PubMedGoogle Scholar
  18. Mackaya VP, Doble A, Bird ED, Spokes EG, Quik M, Iversen LL (1978) 3H-spiroperone binding in normal and schizophrenic post mortem human brain. Life Sci 23: 527–532CrossRefGoogle Scholar
  19. Meltzer HY, Fang VS (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33: 279–286PubMedCrossRefGoogle Scholar
  20. Meltzer HY, Busch D, Fang VS (1981) Hormones, dopamine receptors and schizophrenia. Psychoneuroendocrino logy 6: 17–36CrossRefGoogle Scholar
  21. Meltzer HY, Goode DJ, Fang VS (1978) The effect of psychotropic drugs on endocrine function. I. Neuroleptics, precursors and agonists. In: Lipton MA, Mascio AD, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 509–529Google Scholar
  22. Meltzer MY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2: 19–24PubMedGoogle Scholar
  23. Muller P, Seeman P (1978) Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naxalone receptors. Life Sci 21: 1751–1758CrossRefGoogle Scholar
  24. Müller-Spahn F, Ackenheil M, Albus M, May G, Welter D, Zander K (1984) Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal. Relations to psychopathology and tardive dyskinesia. Psychopharmacology 84. 436–440PubMedCrossRefGoogle Scholar
  25. Müller-Spahn F, Ackenheil M, Albus M, Botschev C, Naber D, Welter D (1986) Neuroendocrine effects of clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology. Psychopharmacology 88: 190–195PubMedCrossRefGoogle Scholar
  26. Naber D, Fischer H, Ackenheil M (1979) Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance? Commun Psychopharmacol 3: 59–65PubMedGoogle Scholar
  27. Nathan RS, Sachar EJ, Ostrow L, Asnis GM, Halbreich U, Halpern FS (1981) Failure of dopaminergic blockade to affect prolactin, growth hormone and cortisol responses to insulin-induced hypoglycemia in schizophrenics. J Clin Endocrinol Metab 52: 807–809PubMedCrossRefGoogle Scholar
  28. Nedopil N, Weiss-Brummer I, Rüther E (1984) Neuroendocrine changes during the course of neuroleptic treatment of schizophrenic patients. In: Shah N, Donald GA (eds) Psychoneuroendocrine dysfunction. Plenum Medical Book, New York, pp. 583–597Google Scholar
  29. Pickar D, Labarca R, Doran AR, (1985) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 43: 669–676CrossRefGoogle Scholar
  30. Owen F, Crow TJ, Poulter, Cross AJ, Longden A, Riley GJ (1978) Dopamine-receptor sensitivity in schizophrenia. Lancet II: 223–226CrossRefGoogle Scholar
  31. Reynolds GP, Rieders P, Jellinger K, Gabriel E (1981) Dopamine receptors and schizophrenia — the neuroleptic drug problem. Neuropharmacology 20: 1319–1320PubMedGoogle Scholar
  32. Rubin RT, Hays SE (1979) Variability of prolactin response to intravenous and intramuscular haloperidol in normal adult men. Psychopharmacology 61: 17–24PubMedCrossRefGoogle Scholar
  33. Rüther E (1986) Wirkungsverlauf der neuroleptischen Therapie: Verlaufsuntersuchungen bei der antipsychotischen Therapie mit Haloperidol and Clozapin. Fischer, StuttgartGoogle Scholar
  34. Sarafoff M, Davis L, Rüther E (1979) Clozapine induced increase of human plasma norepinephrine. J Neurol Trans 46: 145–180CrossRefGoogle Scholar
  35. Sedvall G (1980a) Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs. Prog Biochem Pharmacol 16: 133–140Google Scholar
  36. Sedvall G (1980b) Relationships among biochemical, clinical and pharmaco kinetic variables in neuroleptic treated schizophrenic patients. In: Cattabeni F et al. (eds) Long-term effects of neuroleptics. Adv Biochem Psychopharmacol 24: 521–528Google Scholar
  37. Westerink BHC, Korf J (1975) Influence of drugs on striatal and limbic homovanillic acid concentration in the rat brain. Eur J Pharmacol 33: 31–40PubMedCrossRefGoogle Scholar
  38. Sternberg DE, Charney DS, Henninger GR, Leckmann IJ, Hafstad KM, Landis DH (1982) Impaired presynaptic regulation of norepinephrine in schizophrenia. Arch Gen Psychiatry 39: 285–289PubMedCrossRefGoogle Scholar
  39. Wode-Helgodt B, Eneroth P, Fryö B, Gullberg B, Sedvall G (1977) Effect chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatr Scand 58: 280–293CrossRefGoogle Scholar
  40. Zander KJ, Fisher B, Zimmer R, Ackenheil M (1981) Long-term neuroleptic treatment of chronic schizophrenic patients. Clinical and biochemical effects of withdrawal. Psychopharmacology 73: 43–47PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • E. Rüther
  • F. Müller-Spahn

There are no affiliations available

Personalised recommendations